Armata Pharmaceuticals (ARMP) Current Deferred Revenue (2013 - 2018)

Armata Pharmaceuticals has disclosed Current Deferred Revenue across 6 years of filings, most recently posting $335000.0 for Q4 2018.

• Current Deferred Revenue for Q4 2018 came in at $335000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2018 was $335000.0 (changed N/A YoY), and the FY2018 annual result was $335000.0, changed N/A from the prior year.
• Current Deferred Revenue came in at $335000.0 for Q4 2018 at Armata Pharmaceuticals, up from $20000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $350000.0 in Q2 2015 to a low of $18000.0 in Q3 2016.
• The 5-year median for Current Deferred Revenue is $142000.0 (2015), against an average of $177666.7.
• Across the five-year window, Current Deferred Revenue slumped 92.71% in 2016 and soared 34.88% in 2017, its largest moves.
• Armata Pharmaceuticals' Current Deferred Revenue stood at $244000.0 in 2014, then gained by 0.41% to $245000.0 in 2015, then tumbled by 92.65% to $18000.0 in 2016, then grew by 11.11% to $20000.0 in 2017, then jumped by 1575.0% to $335000.0 in 2018.
• The last three Current Deferred Revenue figures came in at $335000.0 (Q4 2018), $20000.0 (Q3 2017), and $58000.0 (Q2 2017), per Business Quant data.